NFKB1 and idiopathic pulmonary fibrosis: Our results suggest that the SHP-1 agonist SC-43, via targeting the CSF1R/STAT3/NFκB pathway in the alveolar macrophages, may hold great potential in pulmonary fibrosis resolution for IPF patients.